Judah Frommer
Stock Analyst at Morgan Stanley
(4.07)
# 508
Out of 5,148 analysts
181
Total ratings
60.87%
Success rate
8.81%
Average return
Main Sectors:
Stocks Rated by Judah Frommer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GMAB Genmab | Reinstates: Equal-Weight | $34 | $29.65 | +14.67% | 1 | Feb 16, 2026 | |
| RGNX REGENXBIO | Maintains: Overweight | $25 → $18 | $9.24 | +94.81% | 3 | Feb 10, 2026 | |
| ABVX ABIVAX Société Anonyme | Maintains: Overweight | $101 → $145 | $113.11 | +28.19% | 4 | Jan 9, 2026 | |
| BLTE Belite Bio | Initiates: Overweight | $191 | $177.58 | +7.56% | 1 | Jan 6, 2026 | |
| ZBIO Zenas BioPharma | Downgrades: Equal-Weight | $37 → $19 | $25.56 | -25.67% | 2 | Jan 6, 2026 | |
| EVMN Evommune | Initiates: Overweight | $36 | $25.61 | +40.57% | 1 | Dec 1, 2025 | |
| TRVI Trevi Therapeutics | Maintains: Overweight | $18 → $19 | $12.57 | +51.15% | 2 | Nov 14, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Equal-Weight | $25 → $26 | $20.70 | +25.60% | 2 | Jul 2, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Overweight | $46 → $43 | $30.00 | +43.33% | 2 | May 9, 2025 | |
| GLPG Galapagos NV | Downgrades: Underweight | $31 → $22 | $34.09 | -35.46% | 3 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $8 → $6 | $9.33 | -35.69% | 2 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $81 → $106 | $114.05 | -7.06% | 2 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $17.59 | +98.98% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Equal-Weight | $3 | $2.31 | +29.87% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $40 | $1.35 | +2,862.96% | 8 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $3.30 | +293.94% | 5 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $23 | $36.69 | -37.31% | 5 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $50 | $66.37 | -24.66% | 9 | Jul 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $141 | $16.32 | +763.97% | 13 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $9 | $3.68 | +144.57% | 5 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $21 → $22 | $32.83 | -32.99% | 2 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $7 | $5.11 | +36.99% | 3 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $8 | $7.81 | +2.43% | 5 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $77.49 | -40.64% | 5 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6.5 → $7 | $3.27 | +114.07% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $51 → $55 | $10.50 | +423.81% | 3 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $146.32 | -68.56% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $49 | $95.83 | -48.87% | 4 | Nov 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $328 → $370 | $1,002.77 | -63.10% | 2 | Oct 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $31 | $95.41 | -67.51% | 6 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $65 → $76 | $90.48 | -16.00% | 8 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $182 | $152.62 | +19.25% | 9 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $107 | $119.88 | -10.74% | 15 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $90 → $95 | $101.45 | -6.36% | 10 | Jul 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $17.70 | +1.69% | 1 | Jul 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $93 → $116 | $223.48 | -48.09% | 15 | Jun 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $38 | $99.73 | -61.90% | 4 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $22 | $73.99 | -70.27% | 1 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $33 → $35 | $69.05 | -49.31% | 9 | Apr 29, 2020 |
Genmab
Feb 16, 2026
Reinstates: Equal-Weight
Price Target: $34
Current: $29.65
Upside: +14.67%
REGENXBIO
Feb 10, 2026
Maintains: Overweight
Price Target: $25 → $18
Current: $9.24
Upside: +94.81%
ABIVAX Société Anonyme
Jan 9, 2026
Maintains: Overweight
Price Target: $101 → $145
Current: $113.11
Upside: +28.19%
Belite Bio
Jan 6, 2026
Initiates: Overweight
Price Target: $191
Current: $177.58
Upside: +7.56%
Zenas BioPharma
Jan 6, 2026
Downgrades: Equal-Weight
Price Target: $37 → $19
Current: $25.56
Upside: -25.67%
Evommune
Dec 1, 2025
Initiates: Overweight
Price Target: $36
Current: $25.61
Upside: +40.57%
Trevi Therapeutics
Nov 14, 2025
Maintains: Overweight
Price Target: $18 → $19
Current: $12.57
Upside: +51.15%
Apellis Pharmaceuticals
Jul 2, 2025
Maintains: Equal-Weight
Price Target: $25 → $26
Current: $20.70
Upside: +25.60%
Celldex Therapeutics
May 9, 2025
Maintains: Overweight
Price Target: $46 → $43
Current: $30.00
Upside: +43.33%
Galapagos NV
Feb 14, 2025
Downgrades: Underweight
Price Target: $31 → $22
Current: $34.09
Upside: -35.46%
Jan 13, 2025
Maintains: Underweight
Price Target: $8 → $6
Current: $9.33
Upside: -35.69%
Nov 6, 2024
Maintains: Overweight
Price Target: $81 → $106
Current: $114.05
Upside: -7.06%
Oct 8, 2024
Initiates: Overweight
Price Target: $35
Current: $17.59
Upside: +98.98%
Mar 7, 2024
Assumes: Equal-Weight
Price Target: $3
Current: $2.31
Upside: +29.87%
Aug 14, 2023
Reiterates: Outperform
Price Target: $40
Current: $1.35
Upside: +2,862.96%
Aug 9, 2023
Reiterates: Outperform
Price Target: $13
Current: $3.30
Upside: +293.94%
Aug 8, 2023
Reiterates: Outperform
Price Target: $23
Current: $36.69
Upside: -37.31%
Jul 20, 2023
Reiterates: Neutral
Price Target: $50
Current: $66.37
Upside: -24.66%
Jun 23, 2023
Reiterates: Neutral
Price Target: $141
Current: $16.32
Upside: +763.97%
May 12, 2023
Reiterates: Outperform
Price Target: $9
Current: $3.68
Upside: +144.57%
Apr 3, 2023
Maintains: Outperform
Price Target: $21 → $22
Current: $32.83
Upside: -32.99%
Mar 31, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $5.11
Upside: +36.99%
Mar 10, 2023
Downgrades: Neutral
Price Target: $11 → $8
Current: $7.81
Upside: +2.43%
Mar 7, 2023
Reiterates: Outperform
Price Target: $46
Current: $77.49
Upside: -40.64%
Mar 7, 2023
Upgrades: Neutral
Price Target: $6.5 → $7
Current: $3.27
Upside: +114.07%
Feb 28, 2023
Maintains: Outperform
Price Target: $51 → $55
Current: $10.50
Upside: +423.81%
Feb 24, 2023
Reiterates: Outperform
Price Target: $46
Current: $146.32
Upside: -68.56%
Nov 5, 2020
Maintains: Outperform
Price Target: $47 → $49
Current: $95.83
Upside: -48.87%
Oct 6, 2020
Maintains: Neutral
Price Target: $328 → $370
Current: $1,002.77
Upside: -63.10%
Sep 21, 2020
Maintains: Outperform
Price Target: $24 → $31
Current: $95.41
Upside: -67.51%
Sep 21, 2020
Maintains: Outperform
Price Target: $65 → $76
Current: $90.48
Upside: -16.00%
Aug 6, 2020
Assumes: Neutral
Price Target: $182
Current: $152.62
Upside: +19.25%
Aug 6, 2020
Assumes: Outperform
Price Target: $107
Current: $119.88
Upside: -10.74%
Jul 22, 2020
Maintains: Neutral
Price Target: $90 → $95
Current: $101.45
Upside: -6.36%
Jul 21, 2020
Initiates: Outperform
Price Target: $18
Current: $17.70
Upside: +1.69%
Jun 10, 2020
Maintains: Outperform
Price Target: $93 → $116
Current: $223.48
Upside: -48.09%
May 22, 2020
Maintains: Outperform
Price Target: $31 → $38
Current: $99.73
Upside: -61.90%
May 6, 2020
Maintains: Neutral
Price Target: $18 → $22
Current: $73.99
Upside: -70.27%
Apr 29, 2020
Maintains: Neutral
Price Target: $33 → $35
Current: $69.05
Upside: -49.31%